Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
  • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
  • C07K16/3007—Carcino-embryonic Antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

• the present disclosure provides methods for treating a malignant tumor (e.g., advanced solid tumors) with a pharmaceutical composition comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent.
• a malignant tumor e.g., advanced solid tumors
• a pharmaceutical composition comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent.
• cancer immunotherapy had focused substantial effort on approaches that enhance anti-tumor immune responses by adoptive-transfer of activated effector cells, immunization against relevant antigens, or providing non-specific immune- stimulatory agents such as cytokines.
• Exhausted T cells are characterized by the expression of T cell negative regulatory receptors, predominantly CTLA-4, PD-1, and LAG-3, whose action is to limit the cell's ability to proliferate, produce cytokines, and kill target cells and/or to increase Treg activity. Accordingly, a combination therapy comprising an anti-PD-1 antibody and an anti -LAG-3 antibody has had promising results in certain types of cancers. (U.S. Publ. No. 2016/0222116 Al).
• Lymphocyte activation gene-3 (LAG-3; CD223) is a type I transmembrane protein that is expressed on the cell surface of activated CD4+ and CD8+ T cells and subsets of NK and dendritic cells (Triebel et al, J. Exp. Med. 171 : 1393-1405 (1990); Workman et al, J. Immunol. 182(4): 1885-91 (2009)).
• LAG-3 is closely related to CD4, which is a co- receptor for T helper cell activation. Both molecules have 4 extracellular Ig-like domains and require binding to their ligand, major histocompatibility complex (MHC) class II, for their functional activity.
• MHC major histocompatibility complex
• LAG-3 is only expressed on the cell surface of activated T cells and its cleavage from the cell surface terminates LAG-3 signaling. LAG-3 can also be found as a soluble protein but it does not bind to MHC class II and its function is unknown. [0007] It has been reported that LAG-3 plays an important role in promoting regulatory T cell (Treg) activity and in negatively regulating T cell activation and proliferation (Workman et al, J. Immunol. 174:688-695 (2005)). Both natural and induced Treg express increased LAG-3, which is required for their maximal suppressive function (Camisaschi et al, J. Immunol. 184:6545-6551 (2010) and Huang et al, Immunity.
• LAG-3 maintained tolerance to self and tumor antigens via direct effects on CD8+ T cells in 2 murine models (Grosso et al, J. Clin. Invest. 117:3383-3392 (2007)).
• PD-1 Programmed Cell Death 1
• PD-1 is a cell surface signaling receptor that plays a critical role in the regulation of T cell activation and tolerance (Keir et al, Annu Rev Immunol 26:677-704 (2008)). It is a type I transmembrane protein and together with BTLA, CTLA-4, ICOS and CD28, comprise the CD28 family of T cell co-stimulatory receptors.
• PD-1 is primarily expressed on activated T cells, B cells, and myeloid cells (Dong et al, Nat Med. 5: 1365-1369 (1999)). It is also expressed on natural killer (NK) cells (Terme et al, Cancer Res 71 :5393-5399 (2011)).
• PD-1 binding of PD-1 by its ligands, PD-L1 and PD-L2 results in phosphorylation of the tyrosine residue in the proximal intracellular immune receptor tyrosine inhibitory domain, followed by recruitment of the phosphatase SHP-2, eventually resulting in down-regulation of T cell activation.
• One important role of PD-1 is to limit the activity of T cells in peripheral tissues at the time of an inflammatory response to infection, thus limiting the development of autoimmunity (Pardoll Nat Rev Cancer 12:252-264 (2012)).
• PD-1 -deficient mice develop lupus-like autoimmune diseases including arthritis and nephritis, along with cardiomyopathy (Nishimura H, et al, Immunity, 1999; 11 : 141-151; and Nishimura H, et al, Science, 2001; 291 :319-322).
• the consequence is the development of immune resistance within the tumor microenvironment.
• PD-1 is highly expressed on tumor-infiltrating lymphocytes, and its ligands are up-regulated on the cell surface of many different tumors (Dong H, et al, Nat Med 2002; 8:793-800).
• an object of the present invention to provide improved methods (e.g., a composition comprising a combination of an anti-PD-1 antibody, an anti-LAG-3 antibody, and an immunotherapeutic agent) for treating subjects with such tumors (e.g., advanced refractory solid tumors).
• improved methods e.g., a composition comprising a combination of an anti-PD-1 antibody, an anti-LAG-3 antibody, and an immunotherapeutic agent
• tumors e.g., advanced refractory solid tumors.
• the present disclosure provides a method for treating a subject afflicted with a malignant tumor comprising administering to the subject a therapeutically effective amount of (a) LAG-3 inhibitor, (b) a PD-1 pathway inhibitor; and (c) an immunotherapeutic agent, in combination.
• the LAG-3 inhibitor is an anti-LAG-3 antibody or an antigen binding fragment thereof.
• the anti-LAG-3 antibody is a bispecific antibody.
• the anti-LAG-3 antibody or antigen binding fragment thereof comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 7; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:8; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:9; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 10; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 11; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 12.
• the anti-LAG-3 antibody or antigen binding fragment thereof comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:3 and 5, respectively.
• the anti-LAG-3 antibody is BMS 986016, MK-4280 (28G-10), REGN3767, GSK2831781, IMP731 (H5L7BW), BAP050, IMP-701 (LAG-5250), IMP321, TSR-033, LAG525, BI 754111, or FS-118.
• the LAG-3 inhibitor is a soluble LAG-3 polypeptide.
• the soluble LAG-3 polypeptide is a fusion polypeptide.
• soluble LAG-3 polypeptide comprises a ligand binding fragment of the LAG-3 extracellular domain.
• the ligand binding fragment of the LAG-3 extracellular domain comprises an amino acid sequence with at least 90%, at least 95%, at least 98%, or at least 99% sequence identity to SEQ ID NO:44.
• the soluble LAG-3 polypeptide further comprises an Fc domain.
• the PD-1 pathway inhibitor is an anti-PD-1 antibody or antigen binding fragment thereof.
• the anti-PD-1 antibody is pembrolizumab (KEYTRUDA; MK-3475), pidilizumab (CT-011), nivolumab (OPDIVO; BMS-936558), PDR001, MEDI0680 (AMP-514), TSR-042, REGN2810, JS001, AMP- 224 (GSK-2661380), PF-06801591, BGB-A317, BI 754091, or SHR-1210.
• the PD-1 pathway inhibitor is an anti-PD-Ll antibody or antigen binding fragment thereof.
• the anti-PD-Ll antibody is atezolizumab (TECENTRIQ; RG7446; MPDL3280A; R05541267), durvalumab (MEDI4736), BMS-936559, avelumab (bavencio), LY3300054, CX-072 (Proclaim-CX- 072), FAZ053, KN035, or MDX-1105.
• the PD-1 pathway inhibitor is a small molecule drug. In certain embodiments, the PD-1 pathway inhibitor is CA-170. In another embodiment, the PD-1 pathway inhibitor is a cell based therapy. In one embodiment, the cell based therapy is a MiHA-loaded PD-Ll/L2-silenced dendritic cell vaccine. In other embodiments, the cell based therapy is an anti-programmed cell death protein 1 antibody expressing pluripotent killer T lymphocyte, an autologous PD-1 -targeted chimeric switch receptor- modified T lymphocyte, or a PD-1 knockout autologous T lymphocyte.
• the PD-1 pathway inhibitor is an anti-PD-L2 antibody or antigen binding fragment thereof.
• the anti-PD-L2 antibody is rHIgM12B7.
• the PD-1 pathway inhibitor is a soluble PD-1 polypeptide.
• the soluble PD-1 polypeptide is a fusion polypeptide.
• the soluble PD-1 polypeptide comprises a ligand binding fragment of the PD-1 extracellular domain.
• the soluble PD-1 polypeptide comprises a ligand binding fragment of the PD-1 extracellular domain.
• the ligand binding fragment of the PD-1 extracellular domain comprises an amino acid sequence with at least 90%, at least 95%, .at least 98%, or at least 99% sequence identity to SEQ ID NO:29.
• the soluble PD-1 polypeptide further comprises an Fc domain.
• the immunotherapeutic agent is a modulator of CTLA-4 activity, a modulator of CD28 activity, a modulator of CD80 activity, a modulator of CD86 activity, a modulator of 4- IBB activity, an modulator of OX40 activity, a modulator of KIR activity, a modulator of Tim-3 activity, a modulator of CD27 activity, a modulator of CD40 activity, a modulator of GITR activity, a modulator of TIGIT activity, a modulator of CD20 activity, a modulator of CD96 activity, a modulator of IDOl activity, a modulator of STING activity, a modulator of GARP activity, a modulator of A2aR activity, a modulator of CEACAM1 activity, a modulator of CEA activity, a modulator of CD47 activity, a modulator of PVRIG activity, a modulator of TDO activity, a modulator of VISTA activity, a cytokine, a chemokine,
• the immunotherapeutic agent is an immune checkpoint inhibitor.
• the immune checkpoint inhibitor is a CTLA-4 antagonist, a CD80 antagonist, a CD86 antagonist, a Tim-3 antagonist, a TIGIT antagonist, a CD20 antagonist, a CD96 antagonist, a IDOl antagonist, a STING antagonist, a GARP antagonist, a CD40 antagonist, A2aR antagonist, a CEACAM1 (CD66a) antagonist, a CEA antagonist, a CD47 antagonist a PVRIG antagonist, a TDO antagonist, a VISTA antagonist, or a KIR antagonist.
• the immune checkpoint inhibitor is a CTLA-4 antagonist.
• the CTLA-4 antagonist is an anti-CTLA-4 antibody or antigen binding fragment thereof.
• the anti-CTLA-4 antibody is ipilimumab (YERVOY), tremelimumab (ticilimumab; CP-675,206), AGEN-1884, or ATOR-1015.
• the CTLA-4 antagonist is a soluble CTLA-4 polypeptide.
• the soluble CTLA-4 polypeptide is abatacept (Orencia), belatacept (Nulojix), RG2077, or RG-1046.
• the CTLA-4 antagonist is a cell based therapy.
• the CTLA-4 antagonist is an anti-CTLA4 mAb RNA/GITRL RNA-transfected autologous dendritic cell vaccine or an anti-CTLA-4 mAb RNA-transfected autologous dendritic cell vaccine.
• the immune checkpoint inhibitor is a KIR antagonist.
• the KIR antagonist is an anti-KIR antibody or antigen binding fragment thereof.
• the anti-KIR antibody is lirilumab (1-7F9, BMS- 986015, IPH 2101) or IPH4102.
• the immune checkpoint inhibitor is TIGIT antagonist.
• the TIGIT antagonist is an anti-TIGIT antibody or antigen binding fragment thereof.
• the anti-TIGIT antibody is BMS-986207, AB 154, COM902 (CGEN-15137), or OMP-313M32.
• the immune checkpoint inhibitor is Tim-3 antagonist.
• the Tim-3 antagonist is an anti-Tim-3 antibody or antigen binding fragment thereof.
• the anti-Tim-3 antibody is TSR-022 or LY3321367.
• the immune checkpoint inhibitor is a IDOl antagonist.
• the IDOl antagonist is indoximod (NLG8189; l-methyl- D -TRP), epacadostat (INCB-024360, INCB-24360), KHK2455, PF-06840003, navoximod (RG6078, GDC-0919, NLG919), BMS-986205 (F001287), or pyrrolidine-2,5-dione derivatives.
• the immune checkpoint inhibitor is a STING antagonist.
• the STING antagonist is 2' or 3'-mono-fluoro substituted cyclic-di- nucleotides; 2'3'-di-fluoro substituted mixed linkage 2',5' - 3', 5' cyclic-di-nucleotides; 2'- fluoro substituted, bis-3',5' cyclic-di-nucleotides; 2',2"-diF-Rp,Rp,bis-3',5' cyclic-di- nucleotides; or fluorinated cyclic-di-nucleotides.
• the immune checkpoint inhibitor is CD20 antagonist.
• the CD20 antagonist is an anti-CD20 antibody or antigen binding fragment thereof.
• the anti-CD20 antibody is rituximab (RITUXAN; IDEC- 102; IDEC-C2B8), ABP 798, ofatumumab, or obinutuzumab.
• the immune checkpoint inhibitor is CD80 antagonist. In certain embodiments, the CD80 antagonist is an anti-CD80 antibody or antigen binding fragment thereof. In one embodiment, the anti-CD80 antibody is galiximab or AV 1142742. [0029] In one embodiment, the immune checkpoint inhibitor is a GARP antagonist. In some embodiments, the GARP antagonist is an anti-GARP antibody or antigen binding fragment thereof. In certain embodiments, the anti-GARP antibody is ARGX-115.
• the immune checkpoint inhibitor is a CD40 antagonist.
• the CD40 antagonist is an anti-CD40 antibody for antigen binding fragment thereof.
• the anti-CD40 antibody is BMS3h-56, lucatumumab (HCD122 and CHIR-12.12), CHIR-5.9, or dacetuzumab (huS2C6, PRO 64553, RG 3636, SGN 14, SGN-40).
• the CD40 antagonist is a soluble CD40 ligand (CD40-L).
• the soluble CD40 ligand is a fusion polypeptide.
• the soluble CD40 ligand is a CD40-L/FC2 or a monomelic CD40-L.
• the immune checkpoint inhibitor is an A2aR antagonist.
• the A2aR antagonist is a small molecule.
• the A2aR antagonist is CPI-444, PBF-509, istradefylline (KW-6002), preladenant (SCH420814), tozadenant (SYN115), vipadenant (BIIB014), HTL-1071, ST1535, SCH412348, SCH442416, SCH58261, ZM241385, or AZD4635.
• the immune checkpoint inhibitor is a CEACAMl antagonist.
• the CEACAMl antagonist is an anti-CEACAMl antibody or antigen binding fragment thereof.
• the anti-CEACAMl antibody is CM-24 (MK-6018).
• the immune checkpoint inhibitor is a CEA antagonist.
• the CEA antagonist is an anti-CEA antibody or antigen binding fragment thereof.
• the anti-CEA antibody is cergutuzumab amunaleukin (RG7813, RO-6895882) or RG7802 (R06958688).
• the immune checkpoint inhibitor is a CD47 antagonist.
• the CD47 antagonist is an anti-CD47 antibody or antigen binding fragment thereof.
• the anti-CD47 antibody is HuF9-G4, CC- 90002, TTI-621, ALX148, NI-1701, NI-1801, SRF231, or Effi-DEM.
• the immune checkpoint inhibitor is a PVRIG antagonist.
• the PVRIG antagonist is an anti-PVRIG antibody or antigen binding fragment thereof.
• the anti-PVRIG antibody is COM701 (CGEN-15029).
• the immune checkpoint inhibitor is a TDO antagonist.
• the TDO antagonist is a 4-(indol-3-yl)-pyrazole derivative, a 3-indol substituted derivative, or a 3-(indol-3-yl)-pyridine derivative.
• the immune checkpoint inhibitor is a dual IDO and TDO antagonist.
• the dual IDO and TDO antagonist is a small molecule.
• the immune checkpoint inhibitor is a VISTA antagonist.
• the VISTA antagonist is CA-170 or JNJ-61610588.
• the immunotherapeutic agent is an immune checkpoint enhancer or stimulator.
• the immune checkpoint enhancer or stimulator is a CD28 agonist, a 4- IBB agonist, an OX40 agonist, a CD27 agonist, a CD80 agonist, a CD86 agonist, a CD40 agonist, an ICOS agonist, a CD70 agonist, or a GITR agonist.
• the immune checkpoint enhancer or stimulator is an OX40 agonist.
• the OX40 agonist is an anti-OX40 antibody or antigen binding fragment thereof.
• the anti-OX40 antibody is tavolixizumab (MEDI-0562), pogalizumab (MOXR0916, RG7888), GSK3174998, ATOR-1015, MEDI-6383, MEDI-6469, BMS 986178, PF-04518600, or RG7888 (MOXR0916).
• the OX40 agonist is a cell based therapy.
• the OX40 agonist is a GINAKIT cell (iC9-GD2-CD28-OX40- expressing T lymphocytes).
• the immune checkpoint enhancer or stimulator is a CD40 agonist.
• the CD40 agonist is an anti-CD40 antibody or antigen binding fragment thereof.
• the anti-CD40 antibody is ADC-1013 (JNJ-64457107), RG7876 (RO-7009789), HuCD40-M2, APX005M (EPI-0050), or Chi Lob 7/4.
• the CD40 agonist is a soluble CD40 ligand (CD40-L).
• the soluble CD40 ligand is a fusion polypeptide.
• the soluble CD40 ligand is a trimeric CD40-L (AVRE D®).
• the immune checkpoint enhancer or stimulator is a GITR agonist.
• the GITR agonist is an anti-GITR antibody or antigen binding fragment thereof.
• the anti-GITR antibody is BMS-986156, TRX518, GWN323, INCAGN01876, or MEDI1873.
• the GITR agonist is a soluble GITR ligand (GITRL).
• the soluble GITR ligand is a fusion polypeptide.
• the GITR agonist is a cell based therapy.
• the cell based therapy is an anti-CTLA4 mAb RNA/GITRL RNA-transfected autologous dendritic cell vaccine or a GITRL RNA-transfected autologous dendritic cell vaccine.
• the immune checkpoint enhancer or stimulator a 4- IBB agonist.
• the 4- IBB agonist is an anti-4-lBB antibody or antigen binding fragment thereof.
• the anti-4-lBB antibody is urelumab or PF-05082566.
• the immune checkpoint enhancer or stimulator is a CD80 agonist or a CD86 agonist.
• the CD80 agonist or the CD86 agonist is a soluble CD80 or CD86 ligand (CTLA-4).
• CTLA-4 soluble CD80 or CD86 ligand
• the soluble CD80 or CD86 ligand is a fusion polypeptide.
• the CD80 or CD86 ligand is CTLA4-Ig (CTLA4-IgG4m, RG2077, or RG1046) or abatacept (ORENCIA, BMS- 188667).
• the CD80 agonist or the CD86 agonist is a cell based therapy.
• the cell based therapy is MGN1601 (an allogeneic renal cell carcinoma vaccine).
• the immune checkpoint enhancer or stimulator is a CD28 agonist.
• the CD28 agonist is an anti-CD28 antibody or antigen binding fragment thereof.
• the anti-CD28 antibody is TGN1412.
• the CD28 agonist is a cell based therapy.
• the cell based therapy is JCAR015 (anti-CD 19-CD28-zeta modified CAR CD3+ T lymphocyte); CD28CAR/CD137CAR-expressing T lymphocyte; allogeneic CD4+ memory Thl-like T cells/microparticle-bound anti-CD3/anti-CD28; anti- CD 19/CD28/CD3zeta CAR gammaretroviral vector-transduced autologous T lymphocytes KTE-C19; anti-CEA IgCD28TCR-transduced autologous T lymphocytes; anti-EGFRvIII CAR-transduced allogeneic T lymphocytes; autologous CD123CAR- CD28-CD3zeta-EGFRt-expressing T lymphocytes; autologous CD171-specific CAR- CD28 zeta-4-l-BB-EGFRt-expressing T lymphocytes; autologous CD 19C AR-CD28
• the immune checkpoint enhancer or stimulator is a CD27 agonist.
• the CD27 agonist is an anti-CD27 antibody or antigen binding fragment thereof.
• the anti-CD27 antibody is varlilumab (CDX-1127).
• the immune checkpoint enhancer or stimulator is a CD70 agonist.
• the CD70 agonist is an anti-CD70 antibody or antigen binding fragment thereof.
• the anti-CD70 antibody is ARGX-110.
• the immune checkpoint enhancer or stimulator is an ICOS agonist.
• the ICOS agonist is an anti-ICOS antibody or antigen binding fragment thereof.
• the anti-ICOS antibody is BMS986226, MEDI-570, GSK3359609, or JTX-2011.
• the ICOS agonist is a soluble ICOS ligand.
• the soluble ICOS ligand is a fusion polypeptide.
• the soluble ICOS ligand is AMG 750.
• the immunotherapeutic agent is an anti-CD73 antibody or antigen binding fragment thereof.
• the anti-CD73 antibody is MEDI9447.
• the immunotherapeutic agent is a TLR9 agonist.
• the TLR9 agonist is agatolimod sodium.
• the immunotherapeutic agent is a cytokine.
• the cytokine is a chemokine, an interferon, an interleukin, lymphokine, or a member of the tumor necrosis factor family.
• the cytokine is IL-2, IL-15, or interferon-gamma.
• the immunotherapeutic agent is a TGF- ⁇ antagonist.
• the TGF- ⁇ antagonist is fresolimumab (GC-1008); NIS793; IMC-TR1 (LY3022859); ISTH0036; trabedersen (AP 12009); recombinant transforming growth factor-beta-2; autologous HPV-16/18 E6/E7-specific TGF -beta-resistant T lymphocytes; or TGF-beta-resistant LMP-specific cytotoxic T-lymphocytes.
• the immunotherapeutic agent is an iNOS antagonist.
• the iNOS antagonist is N-Acetyle-cysteine (NAC), aminoguanidine, L- nitroarginine methyl ester, or S,S-l,4-phenylene-bis(l,2-ethanediyl)bis-isothiourea).
• the immunotherapeutic agent is a SHP-1 antagonist.
• the immunotherapeutic agent is a CSF1R (colony stimulating factor 1 receptor) antagonist.
• the CSF1R antagonist is an anti- CSF1R antibody or antigen binding fragment thereof.
• the anti- CSF1R antibody is emactuzumab.
• the immunotherapeutic agent is an agonist of a TNF family member.
• the agonist of the TNF family member is ATOR 1016, ABBV-621, or Adalimumab.
• the immunotherapeutic agent is aldesleukin, tocilizumab, or
• the immunotherapeutic agent is a CD160 (NK1) agonist.
• the CD160 (NK1) agonist is an anti-CD160 antibody or antigen binding fragment thereof.
• the anti-CD160 antibody is BY55.
• the LAG-3 inhibitor, PD-1 pathway inhibitor, and the immunotherapeutic agent are formulated for intravenous administration. In some embodiments, the LAG-3 inhibitor, PD-1 pathway inhibitor, and the immunotherapeutic agent are formulated together. In another embodiment, the LAG-3 inhibitor, PD-1 pathway inhibitor, and the immunotherapeutic agent are formulated separately.
• the malignant tumor is selected from the group consisting of a liver cancer, bone cancer, pancreatic cancer, skin cancer, oral cancer, cancer of the head or neck, breast cancer, lung cancer - including small cell and non-small cell lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, cancers of the childhood, lymphocy
• the malignant tumor is non-small cell lung cancer (NSCLC), a virally-related cancer related tumor, or gastric adenocarcinoma.
• NSCLC non-small cell lung cancer
• the malignant tumor is melanoma, gastric cancer, gastroesophageal junction cancer, non- small cell lung cancer, bladder cancer, head and neck squamous cell carcinoma, or renal cell cancer.
• the tumor is lung cancer, melanoma, squamous cell carcinoma of the head and neck, renal cancer, gastric cancer, or hepatocellular carcinoma.
• the anti-LAG-3 antibody or antigen binding fragment thereof and the immunotherapeutic agent are administered as a first line of treatment.
• the LAG-3 inhibitor, PD-1 pathway inhibitor, and the immunotherapeutic agent are administered as a second line of treatment.
• the malignant tumor is refractory to first line treatment.
• the method for treating a subject afflicted with a malignant tumor as described above further comprises the administration of at least one additional therapeutic agent.
• the at least one additional therapeutic agent is a chemotherapeutic agent.
• a “patient” as used herein includes any patient who is afflicted with a cancer (e.g., melanoma).
• a cancer e.g., melanoma
• subject and patient are used interchangeably herein
• administering refers to the physical introduction of a composition comprising a therapeutic agent (e.g., combination of an anti-PD-1 antibody, an anti-LAG-3 antibody, and an additional immunotherapeutic agent) to a subject, using any of the various methods and delivery systems known to those skilled in the art.
• routes of administration include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion.
• parenteral administration means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation.
• Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically.
• Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
• effective treatment refers to treatment producing a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder.
• a beneficial effect can take the form of an improvement over baseline, i.e., an improvement over a measurement or observation made prior to initiation of therapy according to the method.
• a beneficial effect can also take the form of arresting, slowing, retarding, or stabilizing of a deleterious progression of a marker of solid tumor.
• Effective treatment may refer to alleviation of at least one symptom of a solid tumor. Such effective treatment may, e.g., reduce patient pain, reduce the size and/or number of lesions, may reduce or prevent metastasis of a tumor, and/or may slow tumor growth.
• an effective amount refers to an amount of an agent that provides the desired biological, therapeutic, and/or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
• an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) or to prevent or delay other unwanted cell proliferation.
• an effective amount is an amount sufficient to delay tumor development.
• an effective amount is an amount sufficient to prevent or delay tumor recurrence.
• an effective amount can be administered in one or more administrations.
• the effective amount of the drug or composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retard, slow to some extent and may stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and may stop tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
• an "effective amount” is the amount of anti- LAG-3 antibody and the amount of anti-PD-1 antibody, in combination, clinically proven to affect a significant decrease in cancer or slowing of progression of cancer, such as an advanced solid tumor.
• the terms "fixed dose”, “flat dose” and “flat-fixed dose” are used interchangeably and refer to a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
• the fixed or flat dose is therefore not provided as a mg/kg dose, but rather as an absolute amount of the agent (e.g., the anti-LAG-3 antibody and/or anti-PD-1 antibody).
• the term "immunotherapy” refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise modifying an immune response.
• Treatment or “therapy” of a subject refers to any type of intervention or process performed on, or the administration of an active agent (e.g., composition comprising a combination of an anti-PD-1 antibody, an anti-LAG-3 antibody, and an additional immunotherapeutic agent) to the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease.
• an active agent e.g., composition comprising a combination of an anti-PD-1 antibody, an anti-LAG-3 antibody, and an additional immunotherapeutic agent
• cell based therapy refers to the transplantation of delivery of cellular material into a patient for the purpose of treating a disease or disorder (e.g., malignant tumor).
• the cellular material can be a cellular fragment or an intact, living cell (e.g., T lymphocytes, dendritic cells, or stem cells).
• fixed dose with regard to a composition of the invention means that two or more different antibodies in a single composition are present in the composition in particular (fixed) ratios with each other.
• the fixed dose is based on the weight (e.g., mg) of the antibodies.
• the fixed dose is based on the concentration (e.g., mg/ml) of the antibodies.
• the ratio is at least about 1 : 1, about 1 :2, about 1 :3, about 1 :4, about 1 :5, about 1 :6, about 1 :7, about 1 :8, about 1 :9, about 1 : 10, about 1 : 15, about 1 :20, about 1 :30, about 1 :40, about 1 :50, about 1 :60, about 1 :70, about 1 :80, about 1 :90, about 1 : 100, about 1 : 120, about 1 : 140, about 1 : 160, about 1 : 180, about 1 :200, about 200: 1, about 180: 1, about 160: 1, about 140: 1, about 120: 1, about 100: 1, about 90: 1, about 80: 1, about 70: 1, about 60: 1, about 50: 1, about 40: 1, about 30: 1, about 20: 1, about 15: 1, about 10: 1, about 9: 1, about 8: 1, about 7: 1, about 6: 1, about 5: 1, about 4: 1, about 3 : 1, or about 2: 1 mg first antibody to mg second
• the 3 : 1 ratio of a first antibody and a second antibody can mean that a vial can contain about 240 mg of the first antibody and 80 mg of the second antibody or about 3 mg/ml of the first antibody and 1 mg/ml of the second antibody.
• flat dose with regard to the composition of the invention means a dose that is administered to a patient without regard for the weight or body surface area (BSA) of the patient.
• the flat dose is therefore not provided as a mg/kg dose, but rather as an absolute amount of the agent (e.g., the anti-LAG-3 antibody and/or anti- PD-1 antibody).
• a 60 kg person and a 100 kg person would receive the same dose of the composition (e.g., 240 mg of an anti-PD-1 antibody and 80 mg of an anti- LAG-3 antibody in a single fixed dosing formulation vial containing both 240 mg of an anti-PD-1 antibody and 80 mg of an anti- LAG-3 antibody (or two fixed dosing formulation vials containing 120 mg of an anti-PD-1 antibody and 40 mg of an anti- LAG-3 antibody, etc.)).
• the composition e.g., 240 mg of an anti-PD-1 antibody and 80 mg of an anti- LAG-3 antibody in a single fixed dosing formulation vial containing both 240 mg of an anti-PD-1 antibody and 80 mg of an anti- LAG-3 antibody (or two fixed dosing formulation vials containing 120 mg of an anti-PD-1 antibody and 40 mg of an anti- LAG-3 antibody, etc.
• weight based dose means that a dose that is
• administered to a patient is calculated based on the weight of the patient. For example, when a patient with 60 kg body weight requires 3 mg/kg of an anti-LAG-3 antibody in combination with 3 mg/kg of an anti-PD-1 antibody, one can draw the appropriate amounts of the anti-LAG-3 antibody (i.e., 180 mg) and the anti-PD-1 antibody (i.e., 180 mg) at once from a 1 : 1 ratio fixed dosing formulation of an anti-LAG3 antibody and an anti-PD-1 antibody.
• an “antibody” shall include, without limitation, a glycoprotein
• each heavy chain is comprised of a heavy chain variable region (abbreviated herein as V H ) and a heavy chain constant region (abbreviated herein as CH).
• V H heavy chain variable region
• CH heavy chain constant region
• the heavy chain constant region is comprised of a hinge and three domains, CHI, CH2 and CH3.
• each light chain is comprised of a light chain variable region (abbreviated herein as V L ) and a light chain constant region.
• the light chain constant region is comprised of one domain (abbreviated herein as CL).
• CL The V H and V L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
• CDR complementarity determining regions
• FR framework regions
• Each V H and V L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy -terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
• the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
• the constant regions of the antibodies can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system.
• a heavy chain may have the C-terminal lysine or not. Unless specified otherwise herein, the amino acids in the variable regions are numbered using the Kabat numbering system and those in the constant regions are numbered using the EU system.
• An immunoglobulin can be from any of the known isotypes, including IgA,
• IgG secretory IgA, IgD, IgE, IgG, and IgM.
• the IgG isotype is divided in subclasses in certain species: IgGl, IgG2, IgG3 and IgG4 in humans, and IgGl, IgG2a, IgG2b and IgG3 in mice.
• immunotype refers to the antibody class or subclass (e.g., IgM or IgGl) that is encoded by the heavy chain constant region genes.
• antibody includes, by way of example, monoclonal and polyclonal antibodies; chimeric and humanized antibodies; human or nonhuman antibodies; wholly synthetic antibodies; and single chain antibodies.
• a nonhuman antibody may be humanized by recombinant methods to reduce its immunogenicity in man.
• the term "antibody” includes monospecific, bispecific, or multi-specific antibodies, as well as a single chain antibody.
• the antibody is a bispecific antibody.
• the antibody is a monospecific antibody.
• an "IgG antibody” has the structure of a naturally occurring IgG antibody, i.e., it has the same number of heavy and light chains and disulfide bonds as a naturally occurring IgG antibody of the same subclass.
• an anti-ICOS IgGl, IgG2, IgG3 or IgG4 antibody consists of two heavy chains (HCs) and two light chains (LCs), wherein the two heavy chains and light chains are linked by the same number and location of disulfide bridges that occur in naturally occurring IgGl, IgG2, IgG3 and IgG4 antibodies, respectively (unless the antibody has been mutated to modify the disulfide bonds).
• an "isolated antibody” refers to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that binds specifically to PD-1 is substantially free of antibodies that bind specifically to antigens other than PD-1).
• An isolated antibody that binds specifically to PD-1 may, however, have cross-reactivity to other antigens, such as PD-1 molecules from different species.
• an isolated antibody may be substantially free of other cellular material and/or chemicals.
• the antibody may be an antibody that has been altered (e.g., by mutation,
• an antibody may include one or more variant amino acids (compared to a naturally occurring antibody) which change a property (e.g., a functional property) of the antibody.
• a property e.g., a functional property
• numerous such alterations are known in the art which affect, e.g., half-life, effector function, and/or immune responses to the antibody in a patient.
• the term antibody also includes artificial polypeptide constructs which comprise at least one antibody-derived antigen binding site.
• mAb monoclonal antibody
• mAb refers to a non-naturally occurring preparation of antibody molecules of single molecular composition, i.e., antibody molecules whose primary sequences are essentially identical, and which exhibits a single binding specificity and affinity for a particular epitope.
• a monoclonal antibody is an example of an isolated antibody.
• MAbs may be produced by hybridoma, recombinant, transgenic or other techniques known to those skilled in the art.
• a “human” antibody refers to an antibody having variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. Furthermore, if the antibody contains a constant region, the constant region also is derived from human germline immunoglobulin sequences.
• the human antibodies of the invention can include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site- specific mutagenesis in vitro or by somatic mutation in vivo).
• the term "human antibody,” as used herein is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
• a “humanized antibody” refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins. In one embodiment of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen.
• a "humanized” antibody retains an antigenic specificity similar to that of the original antibody.
• a "chimeric antibody” refers to an antibody in which the variable regions are derived from one species and the constant regions are derived from another species, such as an antibody in which the variable regions are derived from a mouse antibody and the constant regions are derived from a human antibody.
• an "anti-antigen” antibody refers to an antibody that binds specifically to the antigen.
• an anti-PD-1 antibody binds specifically to PD-1 and an anti- CTLA-4 antibody binds specifically to CTLA-4.
• an "antigen-binding portion" of an antibody also called an “antigen-binding portion" of an antibody
• binding fragment refers to one or more fragments of an antibody that retain the ability to bind specifically to the antigen bound by the whole antibody. It has been shown that the antigen-binding function of an antibody can be performed by fragments or portions of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding portion" or “antigen-binding fragment” of an antibody, e.g., an anti- ICOS antibody described herein, include:
• Fab fragment fragment from papain cleavage
• a similar monovalent fragment consisting of the VL, VH, LC and CHI domains
• CDR complementarity determining region
• antibody-binding portion or "antigen-binding fragment” of an antibody.
• antigen-binding portion or "antigen-binding fragment” of an antibody.
• Antigen-binding portions can be produced by
• LAG-3 refers to LAG-3
• LAG3 refers to LAG3
• LAG-3 Lymphocyte Activation Gene-3.
• LAG-3 includes human LAG-3 (hLAG-3), variants, isoforms, and species homologs of hLAG-3, and analogs having at least one common epitope with hLAG-3.
• LAG-3 as used herein includes variants, isoforms, homologs, orthologs and paralogs.
• antibodies specific for a human LAG-3 protein may, in certain cases, cross-react with a LAG-3 protein from a species other than human.
• the antibodies specific for a human LAG-3 protein may be completely specific for the human LAG-3 protein and may not exhibit species or other types of cross-reactivity, or may cross-react with LAG-3 from certain other species, but not all other species (e.g., cross-react with monkey LAG-3 but not mouse LAG-3).
• human LAG-3 refers to human sequence LAG-3, such as the complete amino acid sequence of human LAG-3 having Genbank Accession No. NP 002277 (SEQ ID NO: 13).
• mouse LAG-3 refers to mouse sequence LAG- 3, such as the complete amino acid sequence of mouse LAG-3 having Genbank Accession No. NP_032505.
• LAG-3 is also known in the art as, for example, CD223.
• the human LAG-3 sequence may differ from human LAG-3 of Genbank Accession No. NP_002277 by having, e.g., conserved mutations or mutations in non-conserved regions and the LAG-3 has substantially the same biological function as the human LAG-3 of Genbank Accession No. NP_002277 (SEQ ID NO: 44).
• a biological function of human LAG-3 is having an epitope in the extracellular domain of LAG-3 that is specifically bound by an antibody of the instant disclosure or a biological function of human LAG-3 is binding to MHC Class II molecules.
• a particular human LAG-3 sequence will generally be at least 90% identical in amino acid sequence to human LAG-3 of GenBank Accession No. NP 002277 and contains amino acid residues that identify the amino acid sequence as being human when compared to LAG-3 amino acid sequences of other species (e.g., murine).
• a human LAG-3 can be at least 95%, or even at least 96%, 97%, 98%, or 99% identical in amino acid sequence to LAG-3 of GenBank Accession No. NP 002277.
• a human LAG-3 sequence will display no more than 10 amino acid differences from the LAG-3 sequence of GenBank Accession No. NP 002277.
• the human LAG-3 can display no more than 5, or even no more than 4, 3, 2, or 1 amino acid difference from the LAG-3 sequence of GenBank Accession No.
• NP_002277 Percent identity can be determined as described herein.
• the protein Programmed Death 1 is an inhibitory member of the CD28 family of receptors, that also includes CD28, CTLA-4, ICOS and BTLA. PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et al., supra; Okazaki et al. (2002) Curr. Opin. Immunol. 14: 391779-82; Bennett et al. (2003) J Immunol 170:711-8).
• the initial members of the family, CD28 and ICOS were discovered by functional effects on augmenting T cell proliferation following the addition of monoclonal antibodies (Hutloff et al. Nature (1999); 397:263-266; Hansen et al.
• PD-1 was discovered through screening for differential expression in apototic cells (Ishida et al. EMBO J (1992); 11 :3887-95).
• the other members of the family, CTLA-4 and BTLA were discovered through screening for differential expression in cytotoxic T lymphocytes and TH1 cells, respectively.
• CD28, ICOS and CTLA-4 all have an unpaired cysteine residue allowing for homodimerization.
• PD-1 is suggested to exist as a monomer, lacking the unpaired cysteine residue characteristic in other CD28 family members.
• the PD-1 gene is a 55 kDa type I transmembrane protein that is part of the Ig gene superfamily (Agata et al. (1996) Int Immunol 8:765-72).
• PD-1 contains a membrane proximal immunoreceptor tyrosine inhibitory motif (ITEVI) and a membrane distal tyrosine-based switch motif (ITSM) (Thomas, M. L. (1995) J Exp Med 181 : 1953-6; Vivier, E and Daeron, M (1997) Immunol Today 18:286-91).
• ITEVI membrane proximal immunoreceptor tyrosine inhibitory motif
• ITSM membrane distal tyrosine-based switch motif
• PD-1 lacks the MYPPPY motif that is critical for B7-1 and B7-2 binding.
• PD-Ll and PD-L2 Two ligands for PD-1 have been identified, PD-Ll and PD-L2, that have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. (2000) J Exp Med 192: 1027-34; Latchman et al. (2001) Nat Immunol 2:261-8; Carter et al. (2002) Eur J Immunol 32:634-43). Both PD-Ll and PD-L2 are B7 homologs that bind to PD-1, but do not bind to other CD28 family members. PD-Ll is abundant in a variety of human cancers (Dong et al. (2002) Nat. Med. 8:787-9).
• PD-1 deficient animals develop various autoimmune phenotypes, including autoimmune cardiomyopathy and a lupus-like syndrome with arthritis and nephritis (Nishimura et al. (1999) Immunity 11 : 141-51; Nishimura et al. (2001) Science 291 :319-22). Additionally, PD-1 has been found to play a role in autoimmune encephalomyelitis, systemic lupus erythematosus, graft-versus-host disease (GVHD), type I diabetes, and rheumatoid arthritis (Salama et al.
• GVHD graft-versus-host disease
• P-Ll Programmed Death Ligand-1
• PD-Ll is one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) that downregulate T cell activation and cytokine secretion upon binding to PD-1.
• the term "PD-Ll " as used herein includes human PD-Ll (hPD-Ll), variants, isoforms, and species homologs of hPD-Ll, and 5 analogs having at least one common epitope with hPD-Ll .
• the complete hPD-Ll sequence can be found under GenBank Accession No. Q9NZQ7.
• Programmed Death Ligand-2 and "PD-L2” as used herein include human PD-L2 (hPD-L2), variants, isoforms, and species homologs of hPD-L2, and analogs having at least one common epitope with hPD-L2.
• the complete hPD-L2 sequence can be found under GenBank Accession No. Q9BQ51.
• a “cancer” refers a broad group of various diseases characterized by the
• a “cancer” or “cancer tissue” can include a tumor.
• tissue refers to any mass of tissue that results from
• the terms "about” or “comprising essentially of refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system.
• “about” or “comprising essentially of can mean within 1 or more than 1 standard deviation per the practice in the art.
• “about” or “comprising essentially of can mean a range of up to 10% or 20% ⁇ i.e., ⁇ 10% or ⁇ 20%).
• about 3mg can include any number between 2.7 mg and 3.3 mg (for 10%) or between 2.4 mg and 3.6 mg (for 20%).
• the terms can mean up to an order of magnitude or up to 5-fold of a value.
• the meaning of "about” or “comprising essentially of should be assumed to be within an acceptable error range for that particular value or composition.
• any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated.
• Anti-human-LAG-3 antibodies (or VH/VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art. Alternatively, art recognized anti-LAG-3 antibodies can be used. For example, the anti- human LAG-3 antibody described in US2011/0150892 Al, the teachings of which are hereby incorporated by reference, and referred to as monoclonal antibody 25F7 (also known as "25F7" and "LAG3.1) can be used.
• IMP731 H5L7BW
• MK-4280 28G-10
• REGN3767 described in Journal for ImmunoTherapy of Cancer, (2016) Vol. 4, Supp. Supplement 1 Abstract Number: P195, BAP050 described in WO2017/019894
• FMP-701 LAG-525
• IMP321 eftilagimod alpha
• Sym022 TSR-033, MGD013, BI754111, FS118, AVA-017 and GSK2831781.
• anti-LAG-3 antibodies useful in the claimed invention can be found in, for example: WO2016/028672, WO2017/106129, WO2017/062888, WO2009/044273, WO2018/069500, WO2016/126858, WO2014/179664, WO2016/200782,
• Antibodies that compete with any of the above-referenced art-recognized antibodies for binding to LAG-3 also can be used.
• An exemplary anti-LAG-3 antibody is BMS-986016 comprising heavy and light chains comprising the sequences shown in SEQ ID NOs: l and 2, respectively, or antigen binding fragments and variants thereof, as described in US Pat. No. 9,505,839, which is herein incorporated by reference.
• the antibody has the heavy and light chain CDRs or variable regions of BMS-986016. Accordingly, in one embodiment, the antibody comprises CDRl, CDR2, and CDR3 domains of the VH region of BMS-986016 having the sequence set forth in SEQ ID NO: 3, and CDRl, CDR2 and CDR3 domains of the VL region of BMS-986016 having the sequence set forth in SEQ ID NO: 5. In another embodiment, the antibody comprises CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs:7, 8, and 9, respectively, and CDRl, CDR2 and CDR3 domains comprising the sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively.
• the antibody comprises VH and/or VL regions comprising the amino acid sequences set forth in SEQ ID NO:3 and/or SEQ ID NO: 5, respectively.
• the antibody comprises heavy chain variable (VH) and/or light chain variable (VL) regions encoded by the nucleic acid sequences set forth in SEQ ID NO:4 and/or SEQ ID NO:6, respectively.
• the antibody competes for binding with and/or binds to the same epitope on LAG-3 as the above- mentioned antibodies.
• the antibody binds an epitope of human LAG-3 comprising the amino acid sequence PGHPLAPG (SEQ ID NO: 14).
• the antibody binds an epitope of human LAG-3 comprising the amino acid sequence HPAAPSSW (SEQ ID NO: 15) or PAAPSSWG (SEQ ID NO: 16).
• the antibody has at least about 90% variable region amino acid sequence identity with the above-mentioned antibodies (e.g., at least about 90%, 95% or 99% variable region identity with SEQ ID NO:3 or SEQ ID NO:5).
• the anti-LAG-3 antibody is a bispecific antibody.
• the anti-LAG-3 antibody is a bispecific antibody that binds both PD-1 and LAG-3.
• Human monoclonal antibodies that bind specifically to PD-1 with high affinity have been disclosed in U.S. Patent Nos. 8,008,449 and 8,779, 105.
• Other anti-PD- 1 mAbs have been described in, for example, U.S. Patent Nos. 6,808,710, 7,488,802, 8, 168,757 and 8,354,509, and PCT Publication No. WO 2012/145493.
• the anti-PD-1 antibody is nivolumab.
• Nivolumab also known as "OPDIVO ® "; BMS-936558; formerly designated 5C4, BMS-936558, MDX-1106, or ONO-4538
• S228P fully human IgG4
• PD-1 immune checkpoint inhibitor antibody that selectively prevents interaction with PD-1 ligands (PD-L1 and PD-L2), thereby blocking the down-regulation of antitumor T-cell functions
• the anti- PD-1 antibody or fragment thereof cross-competes with nivolumab.
• the anti-PD-1 antibody or fragment thereof binds to the same epitope as nivolumab.
• the anti-PD-1 antibody has the same CDRs as nivolumab.
• the anti-PD-1 antibody is pembrolizumab.
• Pembrolizumab is a humanized monoclonal IgG4 (S228P) antibody directed against human cell surface receptor PD-1 (programmed death- 1 or programmed cell death- 1). Pembrolizumab is described, for example, in U.S. Patent Nos. 8,354,509 and 8,900,587.
• Anti-human-PD-1 antibodies (or VH and/or VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
• art recognized anti-PD-1 antibodies can be used.
• monoclonal antibodies 5C4 referred to herein as Nivolumab or BMS-936558
• 17D8, 2D3, 4H1, 4A11, 7D3, and 5F4 described in WO 2006/121168, the teachings of which are hereby incorporated by reference, can be used.
• Other known PD-1 antibodies include
• the anti-PD-1 antibody is REGN2810.
• the anti-PD-1 antibody is PDR001.
• Another known anti-PD-1 antibody is pidilizumab (CT-011). Antibodies or antigen binding fragments thereof that compete with any of these antibodies or inhibitors for binding to PD-1 also can be used.
• the anti-PD-1 antibody is selected from the group consisting of:
• nivolumab also known as OPDIVO®, 5C4, BMS-936558, MDX-1106, and ONO-4538
• pembrolizumab Merck; also known as KEYTRUDA®, lambrolizumab, and MK-3475; see WO2008/156712
• PDR001 Novartis; see WO 2015/112900
• MEDI- 0680 AstraZeneca; also known as AMP-514; see WO 2012/145493
• cemiplimab also known as REGN-2810; see WO 2015/112800
• JS001 TAIZHOU JUNSHI PHARMA; see Si-Yang Liu et al., J.
• the anti-PD-1 antibody or antigen binding fragment comprises
• the anti-PD-1 antibody or antigen binding fragment thereof binds to the same epitope as
• pembrolizumab In certain embodiments, the anti-PD-1 antibody or antigen binding fragment thereof has the same CDRs as pembrolizumab. In another embodiment, the anti- PD-1 antibody is pembrolizumab.
• Pembrolizumab also known as "KEYTRUDA ® ", lambrolizumab, and MK-3475
• Pembrolizumab has been approved by the FDA for the treatment of relapsed or refractory melanoma.
• the anti-PD-1 antibody or antigen binding fragment thereof cross-competes with BGB-A317.
• the anti-PD-1 antibody or antigen binding fragment thereof binds the same epitope as BGB-A317.
• the anti-PD-1 antibody or antigen binding fragment thereof has the same CDRs as BGB-A317.
• the anti-PD-1 antibody or antigen binding fragment thereof is BGB-A317, which is a humanized monoclonal antibody. BGB-A317 is described in U.S. Publ. No. 2015/0079109.
• Anti-PD-1 antibodies useful for the disclosed compositions also include isolated antibodies that bind specifically to human PD-1 and cross-compete for binding to human PD-1 with nivolumab (see, e.g., U.S. Patent Nos. 8,008,449 and 8,779,105; Int'l Pub. No. WO 2013/173223).
• the ability of antibodies to cross-compete for binding to an antigen indicates that these antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross-competing antibodies to that particular epitope region.
• These cross-competing antibodies are expected to have functional properties very similar to those of nivolumab by virtue of their binding to the same epitope region of PD- 1.
• Cross-competing antibodies can be readily identified based on their ability to cross- compete with nivolumab in standard PD-1 binding assays such as Biacore analysis, ELISA assays or flow cytometry (see, e.g., Int'l Pub. No. WO 2013/173223).
• Anti-PD-1 antibodies usable in the disclosed methods also include isolated
• the anti-PD-1 antibody binds the same epitope as any of the anti-PD- 1 antibodies described herein, e.g., nivolumab.
• cross-compete antibodies The ability of antibodies to cross-compete for binding to an antigen indicates that these monoclonal antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross- competing antibodies to that particular epitope region.
• These cross-competing antibodies are expected to have functional properties very similar those of the reference antibody, e.g., nivolumab, by virtue of their binding to the same epitope region of PD-1.
• Cross- competing antibodies can be readily identified based on their ability to cross-compete with nivolumab in standard PD-1 binding assays such as Biacore analysis, ELISA assays or flow cytometry (see, e.g., WO 2013/173223).
• antibodies or antigen binding fragments thereof that cross-compete for binding to human PD-1 with, or bind to the same epitope region of human PD-1 as, nivolumab are mAbs.
• these cross- competing antibodies can be chimeric antibodies, or humanized or human antibodies.
• Such chimeric, humanized or human mAbs can be prepared and isolated by methods well known in the art.
• Anti-PD- 1 antibodies useful for the compositions of the disclosed invention also include antigen-binding portions of the above antibodies. It has been amply demonstrated that the antigen-binding function of an antibody can be performed by fragments of a full- length antibody. Examples of binding fragments encompassed within the term "antigen- binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab') 2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; and (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody.
• Anti-PD-1 antibodies suitable for use in the disclosed compositions are antibodies that bind to PD-1 with high specificity and affinity, block the binding of PD-L1 and or PD-L2, and inhibit the immunosuppressive effect of the PD-1 signaling pathway.
• the anti-PD- 1 antibody or antigen-binding portion thereof cross- competes with nivolumab for binding to human PD-1.
• the anti-PD- 1 antibody or antigen-binding portion thereof is a chimeric, humanized or human monoclonal antibody or a portion thereof.
• the antibody is a humanized antibody.
• the antibody is a human antibody.
• Antibodies of an IgGl, IgG2, IgG3 or IgG4 isotype can be used.
• the anti-PD-1 antibody or antigen binding fragment thereof comprises a heavy chain constant region which is of a human IgGl or IgG4 isotype.
• the sequence of the IgG4 heavy chain constant region of the anti-PD-1 antibody or antigen binding fragment thereof contains an S228P mutation which replaces a serine residue in the hinge region with the proline residue normally found at the corresponding position in IgGl isotype antibodies.
• the antibody comprises a light chain constant region which is a human kappa or lambda constant region.
• the anti-PD-1 antibody or antigen binding fragment thereof is a mAb or an antigen-binding portion thereof.
• the anti-PD-1 antibody is nivolumab. In other embodiments, the anti-PD-1 antibody is pembrolizumab.
• the anti-PD-1 antibody is chosen from the human antibodies 17D8, 2D3, 4H1, 4A11, 7D3 and 5F4 described in U.S. Patent No. 8,008,449.
• the anti-PD-1 antibody is MEDI0608 (formerly AMP-514), AMP-224, or Pidilizumab (CT-011).
• the anti-PD-1 antibody is a bispecific antibody. In embodiments, the anti-PD-1 antibody is a bispecific antibody that binds both PD-1 and LAG-3. lie.
• Anti-PD-Ll Antibodies are bispecific antibodies.
• Anti-human-PD-Ll antibodies (or VH and/or VL domains derived therefrom) suitable for use in the invention can be generated using methods well known in the art.
• Examples of anti-PD-Ll antibodies useful in the methods of the present disclosure include the antibodies disclosed in US Patent No. 9,580,507, incorporated herein by reference.
• 9,580,507 have been demonstrated to exhibit one or more of the following characteristics: (a) bind to human PD-L1 with a KD of 1 x 10 "7 M or less, as determined by surface plasmon resonance using a Biacore biosensor system; (b) increase T-cell proliferation in a Mixed Lymphocyte Reaction (MLR) assay; (c) increase interferon- ⁇ production in an MLR assay; (d) increase IL-2 secretion in an MLR assay; (e) stimulate antibody responses; and (f) reverse the effect of T regulatory cells on T cell effector cells and/or dendritic cells.
• Anti-PD-Ll antibodies usable in the present invention include monoclonal antibodies that bind specifically to human PD-Ll and exhibit at least one, in some embodiments, at least five, of the preceding characteristics.
• a recognized anti-PD-Ll antibodies can be used.
• human anti-PD-Ll antibodies disclosed in U.S. Pat. No. 7,943,743, the contents of which are hereby incorporated by reference can be used.
• Such anti-PD-Ll antibodies include 3G10, 12A4 (also referred to as BMS-936559), 10A5, 5F8, 10H10, 1B12, 7H1, 11E6, 12B7, and 13G4.
• Other art recognized anti-PD-Ll antibodies which can be used include those described in, for example, U.S. Pat. Nos. 7,635,757 and 8,217,149, U.S. Publication No. 2009/0317368, and PCT Publication Nos.
• Other examples of an anti- PD-Ll antibody include atezolizumab (TECENTRIQ; RG7446), or durvalumab
• avelumab (Bavencio).
• Antibodies or antigen binding fragments thereof that compete with any of these art-recognized antibodies or inhibitors for binding to PD-Ll also can be used.
• the anti-PD-Ll antibody is BMS-936559 (formerly 12A4 or MDX-1105) (see, e.g., U.S. Patent No. 7,943,743; WO 2013/173223).
• the anti-PD-Ll antibody is MPDL3280A (also known as RG7446 and atezolizumab) (see, e.g., Herbst et a/. 2013 J Clin Oncol 31(suppl):3000; U.S. Patent No. 8,217,149), MEDI4736 (Khleif, 2013, In: Proceedings from the European Cancer Congress 2013; September 27-October 1, 2013; Amsterdam, The Netherlands.
• antibodies that cross-compete for binding to human PD-Ll with, or bind to the same epitope region of human PD-Ll as the above-references PD-Ll antibodies are mAbs.
• these cross-competing antibodies can be chimeric antibodies, or can be humanized or human antibodies.
• Such chimeric, humanized or human mAbs can be prepared and isolated by methods well known in the art.
• the anti-PD-Ll antibody is selected from the group consisting of BMS-936559 (also known as 12A4, MDX-1105; see, e.g., U.S.
• the PD-L1 antibody is atezolizumab (TECENTRIQ®).
• Atezolizumab is a fully humanized IgGl monoclonal anti-PD-Ll antibody.
• the PD-L1 antibody is durvalumab (IMFINZITM).
• Durvalumab is a human IgGl kappa monoclonal anti-PD-Ll antibody.
• the PD-L1 antibody is avelumab (BAVENCIO®).
• Avelumab is a human IgGl lambda monoclonal anti-PD-Ll antibody.
• the anti-PD-Ll monoclonal antibody is selected from the group consisting of 28-8, 28-1, 28-12, 29-8, 5H1, and any combination thereof.
• Anti-PD-Ll antibodies usable in the disclosed methods also include isolated
• the anti-PD-Ll antibody binds the same epitope as any of the anti-PD-Ll antibodies described herein, e.g., atezolizumab, durvalumab, and/or avelumab.
• the ability of antibodies to cross-compete for binding to an antigen indicates that these antibodies bind to the same epitope region of the antigen and sterically hinder the binding of other cross-competing antibodies to that particular epitope region.
• cross-competing antibodies are expected to have functional properties very similar those of the reference antibody, e.g., atezolizumab and/or avelumab, by virtue of their binding to the same epitope region of PD-L1.
• Cross- competing antibodies can be readily identified based on their ability to cross-compete with atezolizumab and/or avelumab in standard PD-L1 binding assays such as Biacore analysis, ELISA assays or flow cytometry (see, e.g., WO 2013/173223).
• the antibodies that cross-compete for binding to human are [0133] in certain embodiments.
• PD-L1 with, or bind to the same epitope region of human PD-L1 antibody as,
• Atezolizumab, durvalumab, and/or avelumab are monoclonal antibodies.
• Anti-PD-Ll antibodies usable in the methods of the disclosed invention also include antigen-binding portions of the above antibodies. It has been amply demonstrated that the antigen-binding function of an antibody can be performed by fragments of a full- length antibody.
• Anti-PD-Ll antibodies suitable for use in the disclosed methods or compositions are antibodies that bind to PD-L1 with high specificity and affinity, block the binding of PD-1, and inhibit the immunosuppressive effect of the PD-1 signaling pathway.
• an anti-PD-Ll "antibody” includes an antigen-binding portion or fragment that binds to PD-L1 and exhibits the functional properties similar to those of whole antibodies in inhibiting receptor binding and up- regulating the immune system.
• the anti-PD-Ll antibody or antigen-binding portion thereof cross-competes with atezolizumab, durvalumab, and/or avelumab for binding to human PD-L1. lid.
• immunotherapeutic agent and “immuno-oncology drugs” as used in the present disclosure include any agent, compound, or biologic that is capable of modulating the host's immune system.
• the immunotherapeutic agent can be an immune checkpoint inhibitor an immune checkpoint enhancer or stimulator.
• the immunotherapeutic agents described herein can be used in combination with one or more additional immunotherapeutic agents (e.g., anti-PD-1 antibody and anti-LAG-3 antibody).
• the immunotherapeutic agent is an immune checkpoint inhibitor.
• immunotherapeutic agents include:
• CTLA-4 (CD152) antagonist e.g., YERVOY® (ipilimumab) (U.S. Patent No. 6,984,720); tremelimumab (formerly ticilimumab and CP-675,206); AGEN-1884; and ATOR-1015 (an anti-OX40 and anti-CTLA-4 bispecific antibody)
• a CTLA-4 (CD152) antagonist e.g., YERVOY® (ipilimumab) (U.S. Patent No. 6,984,720); tremelimumab (formerly ticilimumab and CP-675,206); AGEN-1884; and ATOR-1015 (an anti-OX40 and anti-CTLA-4 bispecific antibody)
• a CTLA-4 (CD152) antagonist e.g., YERVOY® (ipilimumab) (U.S. Patent No. 6,984,720); tremelimumab (formerly ticilimumab and
• TIM-3 (HAVCR2) antagonist e.g., TSR-022 and LY3321367
• TIGIT T cell immunoreceptor with Ig and ITIM domains
• an IDOl (indoleamine-2,3-dioxygenase 1) antagonist e.g., indoximod (NLG8189, 1- methyl-D-TRP), epacadostat (INCB-024360), KHK2455, PF-06840003 (PCT Publication No. WO 2016/181348 Al), pyrrolididine-2,5-dione derivatives (PCT Publication No. WO 2015/173764 Al), navoximod (RG6078, GDC-0919, NLG919), and BMS-986205 (F001287));
• KIR killer-cell immunoglobulin-like receptor
• I-7F9 lirilumab (I-7F9, BMS-980615, or IPH2101
• IPH4102 an anti-KIR3DL2 monoclonal antibody
• TDO tryptophan 2,3 -di oxygenase
• 4-(indol-3-yl)-pyrazole derivatives U.S. Patent No. 9, 126,984 B2 and U.S. Publication No. 2016/0263087 Al
• 3-indol substituted derivatives PCT Publication Nos. WO 2015140717 Al, WO 2017025868 Al, WO 2016147144 Al
• 3-(indol-3-yl)-pyridine derivatives U.S. Publication No. 20150225367 Al and PCT Publication No. WO 2015121812 Al
• dual IDO/TDO antagonist e.g., small molecule dual IDO/TDO inhibitors as disclosed in PCT Publication Nos. WO 2015150097 Al, WO 2015082499 A2, WO 2016026772 Al, WO 2016071283 Al, WO 2016071293 A2, and WO 2017007700 Al;
• CD40 antagonist e.g., Lineage BMS3h-56 (U.S. Patent No. 9,475,879), lucatumumab (HCD122 and CHIR-12.12), CHIR-5.9, and dacetuzumab (huS2C6, PRO 64553, RG 3636, SGN 14, SGN-40));
• adenosine A2a receptor (A2aR) antagonist e.g., CPI-444, PBF-509, istradefylline (KW-6002), preladenant (SCH420814), tozadenant (SYN115), vipadenant (BIIB014), HTL-1071, ST1535, SCH412348, SCH442416, SCH58261, ZM241385, and AZD4635 (a small molecule A2aR inhibitor)
• A2aR adenosine A2a receptor (A2aR) antagonist
• VISTA V-domain immunoglobulin (Ig)-containing suppressor of T-cell activation) antagonist (e.g., CA-170 (anti-PD-Ll/L2 and anti-VISTA small molecule) and JNJ- 61610588);
• CEACAM1 (CD66a) antagonist e.g., CM-24 (MK-6018)
• CEA cancerembryonic antigen
• cergutuzumab amunaleukin RG7813, RO-6895882
• RG7802 R06958688
• CD47 antagonist e.g., HuF9-G4, CC-90002, TTI-621, ALX148, NI-1701, NI-1801, SRF231, and Effi-DEM
• PVRIG poliovirus receptor related immunoglobulin domain containing, CD122R
• GARP glycoprotein A repetitions predominant antagonist (e.g., ARGX-115);
• a STING (stimulator of IFN genes) agonist e.g., 2' or 3'-mono-fluoro substituted, or 2'3'-di-fluoro substituted mixed linkage 2', 5' - 3', 5' cyclic-di-nucleotides (PCT Publication No. WO 2017/075477 Al); 2 * -fluoro substituted, bis-3',5' cyclic-di-nucleotides and 2',2"- diF-Rp,Rp,bis-3',5' cyclic-di-nucleotides (PCT Publication No. WO 2016/145102 Al); and Fluorinated cyclic-di-nucleotides (PCT Publication No. WO 2016/096174 Al);
• CD20 agonist e.g., RITUXAN® and ABP 798
• CD80 antagonist e.g., galiximab (IDEC-1 14) and AV 1142742 (RhuDex);
• the immunotherapeutic agent is an immune checkpoint stimulator or enhancer.
• immunotherapeutic agents include:
• a CD28 agonist e.g., TGN1412 (an anti-CD28 antibody) and JCAR015 (an anti- CD 19-CD28-zeta modified chimeric antigen receptor)
• TGN1412 an anti-CD28 antibody
• JCAR015 an anti- CD 19-CD28-zeta modified chimeric antigen receptor
• a CD80 or CD86 agonist e.g., CTLA4-Ig fusion construct (CTLA-4-IgG4m, RG2077, or RG1046); ORENCIA® (abatacept or BMS-188667); and MGN1601;
• ICOS or ICOS-ligand agonist e.g., BMS986226, MEDI-570, GSK3359609, JTX- 2011, and AMG 570;
• 4-1BB (CD137) agonist e.g., urelumab and PF-05082566
• OX40 (CD134 or TNFRS4) agonist e.g., tavolixizumab (MEDI-0562); pogalizumab (MOXR0916, RG7888); GSK3174998; ATOR-1015 (an anti-OX40 and anti-CTLA-4 bispecific antibody); MEDI-6383; MEDI-6469; BMS 986178; PF-04518600; and GINAKIT cells (iC9-GD2-CD28-OX40-expressing T lymphocytes));
• CD27 agonist e.g., varilumab (CDX-1127)
• CDX-1127 varilumab
• CD40 agonist e.g., ADC-1013 (JNJ-64457107), RG7876 (RO-7009789), HuCD40- M2; APX005M (EPI-0050) (U.S. Patent No. 9,556,278); Chi Lob 7/4 (IgGl chimeric agonist CD40 monoclonal antibody));
• CD70 agonist e.g., ARGX-110
• the immunotherapeutic agent is a cytokine, such as a chemokine, an interferon (e.g., interferon-gamma), an interleukin (e.g., aldesleukin (recombinant analog of IL-2 with immunoregulatory and antineoplastic activities), tocilizumab (anti-IL-6 receptor antibody)); a lymphokine, or a member of the tumor necrosis factor (T F) family (e.g., ATOR-1016, ABBV-621, and adalimumab).
• T F tumor necrosis factor
• immunotherapeutic agents include: CSFIR (colony stimulating factor 1 receptor, CD 115) antagonist (e.g., emactuzumab); Toll-like receptor 9 (TLR9) agonist (e.g., agatolimod sodium); CD160 ( K1) agonist (e.g., BY55); CD73 antagonist (5'- nucleotidase or ecto-5'-nucleotidase ) (e.g., MEDI9447); iNOS (inducible NO synthase, NOS2) antagonist (e.g., N-Acetyle-cysteine (NAC), aminoguanidine, L-nitroarginine methyl ester, ⁇ -S'-l ⁇ -phenylene- ⁇ / l ⁇ -ethanediy ⁇ w-isothiourea); and SHP-1 (Src homology 2 domain-containing protein tyrosine phosphatase 1) antagonist (see Watson et al, Biochem Soc Trans,
• compositions suitable for administration to human patients are typically formulated for parenteral administration, e.g., in a liquid carrier, or suitable for reconstitution into liquid solution or suspension for intravenous administration.
• compositions typically comprise a pharmaceutically acceptable carrier.
• pharmaceutically acceptable means approved by a government regulatory agency or listed in the U.S. Pharmacopeia or another generally recognized pharmacopeia for use in animals, particularly in humans.
• carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
• Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, glycerol polyethylene glycol ricinoleate, and the like.
• Water or aqueous solution saline and aqueous dextrose and glycerol solutions may be employed as carriers, particularly for injectable solutions (e.g., comprising an anti-PD-1 antibody, an anti-LAG-3 antibody, and/or another immunotherapeutic agent).
• Liquid compositions for parenteral administration can be formulated for administration by injection or continuous infusion. Routes of administration by injection or infusion include intravenous, intraperitoneal, intramuscular, intrathecal and subcutaneous.
• the composition comprising an anti-PD-1 antibody, an anti-LAG-3 antibody, and an immunotherapeutic agent are administered intravenously (e.g., in separate formulations or together (in the same formulation or in separate formulations)).
• Solid tumors cancer e.g., advanced refractory solid tumors
• a combination of an anti-LAG- 3 antibody, a PD-1 pathway inhibitor, and an additional immunotherapeutic agent e.g., an anti-LAG- 3 antibody, a PD-1 pathway inhibitor, and an additional immunotherapeutic agent.
• cancers that may be treated using the methods of the invention, include liver cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, oral cancer breast cancer, lung cancer - including small cell and non-small cell lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, solid tumors of childhood, lymphocytic lympho
• the human patient suffers from non-small cell lung cancer
• NSCLC Newcastle disease virus
• HPV human papilloma virus
• HPV human papilloma virus
• gastric adenocarcinoma gastric adenocarcinoma.
• HPV-related tumor is HPV+ head and neck cancer (HNC).
• HNC head and neck cancer
• the gastric adenocarcinoma is associated with Epstein-Barr virus (EBV) infection.
• EBV Epstein-Barr virus
• Patients can be tested or selected for one or more of the above described clinical attributes prior to, during or after treatment.
• Combination therapies provided herein involve administration of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and another immunotherapeutic agent that blocks an inhibitory immune receptor (e.g., a receptor, which upon binding to its natural ligand, inhibits/neutralizes activity, such as cytotoxic activity), to treat subjects having malignant tumors (e.g., advanced refractory solid tumors).
• an inhibitory immune receptor e.g., a receptor, which upon binding to its natural ligand, inhibits/neutralizes activity, such as cytotoxic activity
• the invention provides an anti-LAG-3 antibody, an anti-PD-1 antibody, and another immunotherapeutic agent, in combination, according to a defined clinical dosage regimen, to treat subjects having a malignant tumor (e.g., an advanced refractory solid tumor).
• a malignant tumor e.g., an advanced refractory solid tumor.
• the anti-LAG-3 antibody is BMS- 986016.
• the anti-PD-1 antibody is BMS-936558.
• dosage regimens are adjusted to provide the optimum desired response (e.g., an effective response).
• adjunctive or combined administration includes simultaneous administration of the compounds in the same or different dosage form, or separate administration of the compounds (e.g., sequential administration).
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and the immunotherapeutic agent can be simultaneously administered in a single formulation.
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and the immunotherapeutic agent can be formulated for separate administration and are administered concurrently or sequentially (e.g., one antibody is administered within about 30 minutes prior to administration of the second antibody), and in any order.
• the anti-PD-1 antibody can be administered first, followed by (e.g., immediately followed by) the administration of the anti-LAG-3 antibody and/or the immunotherapeutic agent.
• the PD-1 pathway inhibitor is administered prior to administration of the anti-LAG-3 antibody and/or the immunotherapeutic agent.
• the PD-1 pathway inhibitor is administered after administration of the anti-LAG-3 antibody and/or the immunotherapeutic agent.
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and the immunotherapeutic agent are administered concurrently. Such concurrent or sequential administration preferably results in all three components being simultaneously present in treated patients.
• Suitable treatment protocols for treating a malignant tumor in a human patient include, for example, administering to the patient an effective amount of each of:
• an anti-LAG-3 antibody such as one comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:5,
• an anti-PD-1 antibody such as one comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 19, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:21,
• the method comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, at least four doses of the anti-LAG-3 antibody are administered at a flat dose of about 1, 3, 10, 20, 50, 80, 100, 130, 150, 180, 200, 240 or 280 mg, at least four doses of the anti-PD-1 antibody are administered at flat dose of about 50, 80, 100, 130, 150, 180, 200, 240 or 280 mg, and at least four doses of the immunotherapeutic agent are administered at a flat dose of about.
• four doses of the anti-LAG-3 antibody are administered at a dose of 0.01, 0.03, 0.25, 0.1, 0.3, 1 or 3, 5, 8 or 10 mg/kg body weight
• four doses of the anti- PD-1 antibody are administered at a dose of 0.1, 0.3, 1, 3, 5, 8 or 10 mg/kg body weight
• four doses of the immunotherapeutic agent are administered at a flat dose of about.
• the dose of the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent is calculated per body weight, e.g., mg/kg body weight.
• the dose of the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent is a flat-fixed dose.
• the dose of the anti -LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent is varied over time.
• the anti-LAG-3 antibody, the PD-1 antibody, and/or the immunotherapeutic agent may be initially administered at a high dose and may be lowered over time.
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent is initially administered at a low dose and increased over time.
• the amount of the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent administered is constant for each dose. In another embodiment, the amount of antibody and/or immunotherapeutic agent administered varies with each dose. For example, the maintenance (or follow-on) dose of the antibody and/or immunotherapeutic agent can be higher or the same as the loading dose which is first administered. In another embodiment, the maintenance dose of the antibody and/or immunotherapeutic agent can be lower or the same as the loading dose.
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent are formulated for intravenous administration.
• the anti-PD-1 antibody is administered on Days 1, 15, 29, and 43 of each cycle.
• the anti-LAG-3 antibody is administered on Days 1, 15, 29, and 43 of each cycle.
• the therapeutic agent is administered on Days 1, 15, 29, and 43 of each cycle.
• the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent are administered once per week, once every or three two weeks, once per month or as long as a clinical benefit is observed or until there is a complete response, confirmed progressive disease or unmanageable toxicity.
• a cycle of administration is eight weeks, which can be repeated, as necessary.
• the treatment consists of up to 12 cycles.
• 4 doses of the PD-1 pathway inhibitor are administered per eight week cycle. In another embodiment, 4 doses of the PD-1 pathway inhibitor are administered per eight week cycle. In some embodiment, 4 doses of the therapeutic agent are administered per eight week cycle.
• the PD-1 pathway inhibitor, the anti-LAG-3 antibody, and/or the immunotherapeutic agent are administered as a first line of treatment (e.g., the initial or first treatment).
• the PD-1 pathway inhibitor, the anti- LAG-3 antibody, and/or the immunotherapeutic agent are administered as a second line of treatment (e.g., after the initial or first treatment, including after relapse and/or where the first treatment has failed).
• the invention features any of the aforementioned embodiments, wherein the anti-PD-1 antibody is replaced by, or combined with, an anti-PD-Ll or anti- PD-L2 antibody.
• Patients treated according to the methods disclosed herein preferably experience improvement in at least one sign of cancer.
• improvement is measured by a reduction in the quantity and/or size of measurable tumor lesions.
• lesions can be measured on chest x-rays or CT or MRI films.
• cytology or histology can be used to evaluate responsiveness to a therapy.
• the patient treated exhibits a complete response (CR), a partial response (PR), stable disease (SD), immune-related complete disease (irCR), immune-related partial response (irPR), or immune-related stable disease (irSD).
• the patient treated experiences tumor shrinkage and/or decrease in growth rate, i.e., suppression of tumor growth.
• unwanted cell proliferation is reduced or inhibited.
• one or more of the following can occur: the number of cancer cells can be reduced; tumor size can be reduced; cancer cell infiltration into peripheral organs can be inhibited, retarded, slowed, or stopped; tumor metastasis can be slowed or inhibited; tumor growth can be inhibited; recurrence of tumor can be prevented or delayed; one or more of the symptoms associated with cancer can be relieved to some extent.
• administration of effective amounts of the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and the immunotherapeutic agent according to any of the methods provided herein produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in number of metastatic lesions appearing over time, complete remission, partial remission, or stable disease.
• the improvement of clinical benefit rate is about 20% 20%, 30%, 40%, 50%, 60%, 70%, 80% or more compared to an anti-LAG-3 antibody, a PD-1 pathway inhibitor, or an immunotherapeutic agent alone.
• kits which include a pharmaceutical composition comprising an anti-LAG-3 antibody (e.g., BMS-986016), a PD-1 pathway inhibitor (e.g., BMS-936558), an immunotherapeutic agent, and a pharmaceutically-acceptable carrier, in a therapeutically effective amount adapted for use in the preceding methods.
• the kits optionally also can include instructions, e.g., comprising administration schedules, to allow a practitioner (e.g., a physician, nurse, or patient) to administer the composition contained therein to administer the composition to a patient having cancer (e.g., a solid tumor).
• the kit also can include a syringe.
• kits include multiple packages of the single-dose pharmaceutical compositions each containing an effective amount of the anti-LAG-3 antibody, the PD-1 pathway inhibitor, and/or the immunotherapeutic agent for a single administration in accordance with the methods provided above.
• Instruments or devices necessary for administering the pharmaceutical composition(s) also may be included in the kits.
• a kit may provide one or more pre-filled syringes containing an effective amount of the anti-LAG-3 antibody, the anti-PD-1 antibody, and/or the immunotherapeutic agent.
• the present invention provides a kit for treating a malignant tumor in a human patient, the kit comprising, for example:
• an anti-LAG-3 antibody such as one comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO:3, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO: 5;
• a dose of PD-1 pathway inhibitor such as an antibody antibody comprising CDRl, CDR2 and CDR3 domains of the heavy chain variable region having the sequence set forth in SEQ ID NO: 19, and CDRl, CDR2 and CDR3 domains of the light chain variable region having the sequence set forth in SEQ ID NO:21;
• Nivolumab Monotherapy Treatment of Malignant Tumor with Nivolumab Monotherapy v. Nivolumab + BMS 986016 (anti-LAG-3 antibody) + Immunotherapeutic Agent
• a pharmaceutical composition comprising a combination of nivolumab, BMS 986016, and an immunotherapeutic agent is tested in patients with recurrent metastatic tumors.
• a formal pairwise comparison of OS among experimental arms i.e., nivolumab monotherapy v. nivolumab + BMS 986016 + immunotherapeutic agent combination therapy is conducted.
• the study also compares the progression-free survival (PFS) and the objective response rate (ORR), based on Blinded Independent Central Review (BICR) assessment of the combination of nivolumab, BMS 986016, and an immunotherapeutic agent ("combined therapy") to nivolumab monotherapy in subjects with recurrent metastatic tumor. Differences in PFS and ORR between the different arms are evaluated.
• PFS progression-free survival
• ORR objective response rate
• Other objectives of the study include: 1) assessing the overall safety and tolerability of the combined therapy compared to the nivolumab monotherapy; 2) characterizing pharmacokinetics of the combined therapy and explore exposure-safety and exposure-efficacy relationships; 3) characterizing the immunogenicity of the combined therapy; 4) characterizing immune correlates of the combined therapy; 5) assessing predictive tumor and peripheral biomarkers of clinical response to the combined therapy; and 6) assessing overall health status using the EQ-5D index and visual analogue scale in subjects treated with the combined therapy.
• the study is an open label, 2-arm, randomized study in adult (greater than or equal to 18 years of age) male and female subjects, with stage IV or recurrent non-small cell lung cancer (NSCLC), PD-L1 positive or negative, previously untreated for advanced disease.
• NSCLC non-small cell lung cancer
• Key inclusion criteria include: 1) ECOG Performance Status of greater than or equal to 1; 2) Patients with histologically confirmed Stage IV or recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer classification squamous or non-squamous histology), with no prior systemic anticancer therapy (including EGFR and ALK inhibitors) given as primary therapy for advanced or metastatic disease; and 3) Measurable disease by CT or MRI per RECIST 1.1 criteria.
• Key exclusion criteria include: 1) Subjects with known EGFR mutations which are sensitive to available targeted inhibitor therapy; 2) Subjects with known ALK translocations which are sensitive to available targeted inhibitor therapy; 3) Subjects with untreated CNS metastases; 4) Subjects with an active, known or suspected autoimmune disease (subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll); and 5) Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization (inhaled or topical steroids, and adrenal replacement steroid > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease).
• corticosteroids > 10 mg daily prednisone equivalent
• Subjects are randomized 1 : 1 : 1 : 1, and stratified by histology (Squamous versus
• Non-squamous and PD-L1 status are determined by immunohistochemical (IHC) staining of PD-L1 protein in a tumor sample submitted prior to randomization. Subjects are identified as PD-L1 positive if greater than or equal to 5% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells is observed, or PD- Ll negative if less than 5% tumor cell membrane staining in a minimum of a hundred evaluable tumor cells is observed.
• IHC immunohistochemical
• nivolumab and BMS 986016 may be administered as 30 minute infusions
• On-study tumor assessment begins at Week 6 post randomization ( ⁇ 7 days) and is performed every 6 weeks ( ⁇ 7 days) until Week 48. After Week 48, tumor assessment is performed every 12 weeks ( ⁇ 7 days) until progression or treatment discontinuation, whichever occurs later. Subjects receiving nivolumab or the combined therapy beyond investigator-assessed RECIST 1.1-defined progression must also continue tumor assessments until such treatment is discontinued. Enrollment will end after approximately 1200 subjects are randomized.
• the primary endpoint of the study is Overall Survival (OS). The duration of the study from start of enrollment to analysis of the primary OS endpoint is expected to be approximately 48 months.
• Nivolumab 240 mg is administered intravenously (IV) on day 1 of each cycle over
• Nivolumab 1 mg/kg is administered IV over 30 minutes combined with BMS
• the post-treatment follow-up begins when the decision to discontinue a subject from all treatment is made; this includes optional continuation maintenance therapy.
• Subjects who discontinue treatment for reasons other than disease progression will continue to have tumor assessments (if clinically feasible) until progression or the start of any subsequent therapy, whichever occurs first.
• Subjects are followed for drug-related toxicities until these toxicities resolve, return to baseline or are deemed irreversible. All adverse events are documented for a minimum of 100 days after the last dose of study medication. After completion of the first two follow-up visits, subjects are followed every 3 months for survival.
• OS is a primary endpoint for this study. If OS superiority is demonstrated for at least one comparison, a gate keeping testing approach for the key secondary endpoints will be applied to additional experimental vs. control comparisons as described in the statistical analysis plan. Key secondary endpoints include PFS and ORR based on BICR assessments.
• Each of the three primary OS analyses will be conducted using a two-sided log- rank test stratified by histology and PD-L1 status in all randomized subjects using Hochberg's procedure to address multiplicity.
• Hazard ratios (HR) and corresponding two- sided (1-adjusted a) % confidence intervals (CI) will be estimated using a Cox proportional hazard model, with treatment group as a single covariate, stratified by the above factors.
• OS curves, OS medians with 95% CIs, and OS rates at 12 and 24 months with 95%) CIs will be estimated using Kaplan-Meier methodology. If OS superiority is demonstrated for at least one comparison, a gatekeeping testing approach for the key secondary endpoints will be applied to additional experimental vs. control comparisons as described in the statistical analysis plan. The key secondary endpoints will be tested in the following hierarchical order:
• PFS based on BICR assessments
• analyses will be conducted using a two-sided log- rank test stratified by histology and PD-Ll status in all randomized subjects to compare each of the three experimental treatments to the control group.
• HRs and corresponding two-sided (1 -adjusted a) % CIs will be estimated using a Cox proportional hazard model, with treatment group as a single covariate, stratified by the above factors.
• PFS curves, PFS medians with 95% CIs, and PFS rates at 6 and 12 months with 95% CIs will be estimated using Kaplan-Meier methodology.
• ORR based on BICR assessments
• analyses will be conducted using a two-sided Cochran-Mantel-Haenszel (CMH) test stratified by PD-Ll status and histology to compare each of the three experiment treatments to the control group.
• CMH Cochran-Mantel-Haenszel
• Associated odds ratios and (1-adjusted a) % CI will also be calculated.
• ORRs and their corresponding 95% exact CIs will be calculated using the Clopper-Pearson method for each of the four treatment groups.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Immunology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Cell Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Oncology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=62751546

Family Applications (2)

Family Applications After (1)

Country Status (11)

Families Citing this family (69)

Family Cites Families (99)

• 2018
  • 2018-05-30 JP JP2019566156A patent/JP2020522495A/ja active Pending
  • 2018-05-30 AU AU2018277559A patent/AU2018277559A1/en not_active Abandoned
  • 2018-05-30 MX MX2019012038A patent/MX2019012038A/es unknown
  • 2018-05-30 EP EP18734678.8A patent/EP3630842A2/en not_active Withdrawn
  • 2018-05-30 CN CN201880036532.7A patent/CN110691795A/zh active Pending
  • 2018-05-30 KR KR1020197038188A patent/KR20200010500A/ko not_active Withdrawn
  • 2018-05-30 BR BR112019018759A patent/BR112019018759A2/pt unknown
  • 2018-05-30 EP EP23174625.6A patent/EP4245375A3/en active Pending
  • 2018-05-30 CA CA3060989A patent/CA3060989A1/en active Pending
  • 2018-05-30 WO PCT/US2018/035125 patent/WO2018222711A2/en not_active Ceased
  • 2018-05-30 US US16/616,569 patent/US20210340250A1/en not_active Abandoned
• 2019
  • 2019-09-03 IL IL26909019A patent/IL269090A/en unknown
• 2022
  • 2022-08-10 US US17/818,838 patent/US20230111786A1/en not_active Abandoned
• 2023
  • 2023-07-06 JP JP2023111618A patent/JP2023126946A/ja active Pending
• 2025
  • 2025-01-16 US US19/025,264 patent/US20250163152A1/en active Pending
  • 2025-03-31 AU AU2025202283A patent/AU2025202283A1/en active Pending
• 2026
  • 2026-01-08 JP JP2026001835A patent/JP2026062993A/ja active Pending

Also Published As

Similar Documents

Legal Events